The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Is The Excess Mortality Amongst Tuberculosis Survivors Explained By Chronic Pulmonary Aspergillosis? Investigating Burden, Diagnosis, And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Chronic pulmonary aspergillosis (CPA) is a serious lung infection due to the mould Aspergillus. It affects people with damaged lungs, such as those who have had tuberculosis. In Vietnam, TB is extremely common, and there should be many cases of CPA. However, because diagnostic facilities are poor, CPA is often wrongly labelled as failed TB treatment, and patients receive the wrong therapy. My research will determine the size of the problem in Vietnam and how best to address it.
Microbial Restoriation In Crohn's Disease: A Randomised Trial Of Faecal Microbial Transplanatation In Crohn's Disease
Funder
National Health and Medical Research Council
Funding Amount
$487,123.00
Summary
Crohn's disease causes inflammation and damage to the digestive tract. Compelling evidence suggests that the bacteria in the gut play an important role in the onset of disease. Changing the gut bacteria through the administration of healthy stool to a patient, faecal microbiota transplantation (FMT), is safe and may be effective. This placebo controlled trial will determine whether FMT (delivered via capsule) can control inflammation in Crohn's. Results will change current treatment paradigms.